scPharmaceuticals Inc. to Present at the Jefferies 2019 London Healthcare Conference
14 nov. 2019 08h00 HE
|
scPharmaceuticals Inc.
BURLINGTON, Mass., Nov. 14, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports Third Quarter 2019 Financial Results and Provides Business Update
12 nov. 2019 08h00 HE
|
scPharmaceuticals Inc.
Continued progress on FUROSCIX®; confirming the planned resubmission of FUROSCIX® NDA with the FDA by mid-year 2020 remains on track Company initiated the second of two planned human factors studies ...
scPharmaceuticals Inc. Provides FUROSCIX® Update and Announces Completion of $20.0 Million Term Loan Agreement
18 sept. 2019 08h00 HE
|
scPharmaceuticals Inc.
Continued progress on FUROSCIX; confirming the planned resubmission of FUROSCIX NDA with the FDA by mid-year 2020 Completed $20.0 Million Term Loan with Solar Capital Ltd. and Silicon Valley Bank ...
scPharmaceuticals Inc. Reports Second Quarter 2019 Financial Results and Provides Business Update
07 août 2019 08h00 HE
|
scPharmaceuticals Inc.
Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission Company successfully completed the first...
scPharmaceuticals Inc. to Present at the 2019 Wedbush PacGrow Healthcare Conference
06 août 2019 08h00 HE
|
scPharmaceuticals Inc.
BURLINGTON, Mass., Aug. 06, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX®
16 juil. 2019 08h00 HE
|
scPharmaceuticals Inc.
Type C Meeting confirmed that FDA does not believe additional clinical safety, efficacy, or pharmacology studies will be required to support NDA resubmission and review FDA confirmed that the...
scPharmaceuticals Inc. to Present at Upcoming Investor Conferences
30 mai 2019 08h00 HE
|
scPharmaceuticals Inc.
BURLINGTON, Mass., May 30, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...
scPharmaceuticals Inc. Reports First Quarter 2019 Financial Results and Provides Business Update
08 mai 2019 08h00 HE
|
scPharmaceuticals Inc.
Type C Meeting to solidify re-filing plans for FUROSCIX® scheduled with the U.S. Food and Drug Administration (FDA) for June 2019 Resubmission of FURSOCIX New Drug Application (NDA) with the FDA in...
scPharmaceuticals Inc. Reports Fourth Quarter and Year Ended 2018 Financial Results and Provides Business Update
21 mars 2019 08h00 HE
|
scPharmaceuticals Inc.
Signed development agreement with West Pharmaceutical Services for next-generation FUROSCIX® On-Body Infusor Resubmission of FURSOCIX with the U.S. Food and Drug Administration (FDA) by year-end 2020...
scPharmaceuticals Inc. to Present at the 8th Annual SVB Leerink Partners Global Healthcare Conference
21 févr. 2019 08h00 HE
|
scPharmaceuticals Inc.
BURLINGTON, Mass., Feb. 21, 2019 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to...